A Review of Hormonal Dynamics and Clinicopathological Features in Women with Breast Cancer

P-ISSN: 1680-9300
E-ISSN: 2790-2129
Vol. (26), No. (2)
pp. 01-13

[1] Rusul A. Alshammary, [2] Marwa M. Al-Attar, [3] Wijdan M. Hameed

[1] Department of Microbiology, College of Science, Mustansiriah University, Baghdad, Iraq.

[2] Department of Biology, College of Science, Mustansiriah University, Baghdad, Iraq.

[3] Department of Chemistry, College of Science, Mustansiriah University, Baghdad, Iraq.

Abstract:

Breast cancer is a complex, diverse disease that has an effect on people around the world. The rise of breast cancer is associated with hormonal imbalance and emphasizes the importance of understanding complex relationships between hormones and breast tissue. This intensive study intends to detect the importance of hormonal breast cancer imbalance, and analyzes how to affect the growth of large hormones such as estrogen and progesterone. Review checks how hormone imbalance affects the breast tissue. In addition, it discusses the importance of hormone samples for clinical and medical decisions, as well as considering hormonal imbalance as a method to estimate the risk of breast cancer. The study also provides observations of benefits, boundaries and ongoing research projects to adapt to the effectiveness of hormone therapy and remove resistance in the treatment of breast cancer. In this sense, it is important to study the role of hormone dynamics in pathophysiology for breast cancer for the development of our knowledge of the situation and the development of more adapted, effective treatment. Understanding how hormones affect the initiation, spread and resistance of cancer treatment, it is necessary to improve the patient's results and reduce the global stress of breast cancer. The purpose of this review is to provide a comprehensive analysis of how hormonal changes affect breast cancer pathophysiology and the clinical importance of major clinical-pathological features. It tries to improve the results of the treatment by integrating existing data and providing possible paths for the patient's satisfaction with sequence, hormone -focused therapy.

Keywords: Breast Cancer, Hormonal Dynamics, Estrogen, Progesterone.

1. Introduction:

Breast cancer remains one of the most prevalent and lethal cancers affecting women globally, significantly contributing to cancer-related morbidity and mortality rates. Hormonal dynamics, especially the functions of estrogen and progesterone, which are important intermediaries of nipple growth and carcinogenesis, have a significant impact on its beginning and progress. Hormonal imbalance can promote the growth and spread of cancer, which can lead to aberrant cellular existence, discrimination and dissemination (Łukasiewicz et al., 2021). One of the most popular and deadly forces that affect women around the world, and breast cancer has a major impact on public health. Multicultural etiology of breast cancer has genetic, environmental and hormonal

Journal of Prospective Researches
Vol. (26), No. (2)
The paper was received on September 5, 2025; accepted on October 27, 2025; and published on April 29, 2026.
Corresponding author's e-mail:
rusulabood.mc.s.zoo.2020@uomustansiriyah.edu.iq

10.61704/pr.523

variables. Of these, hormones are important for the development of breast cancer, courses and results. Over the past many years, our knowledge of hormonal dynamics of breast most cancers have developed substantially, which has helped to make clear how hormones have an effect on the improvement of the sickness (Wu & Lin, 2024).

Tumor length, degree, receptor position (ER, PR, and HER2), lymph node participation and other medical institution pathological capabilities provide big perception into the organic activity of breast most cancers and direct remedy technique. These properties display a complex relationship among endocrine variables and molecular tumor homes whilst tested in combination with hormonal dynamics. In a unique way, a profound understanding of these interactions has made it possible for hormone receptor tramyddus to diagnose, assess, and improve individual measures (Wang & Xue 2023).

Breast most cancer biology has long been associated with hormones containing progesterone, estrogen and prolactin. In addition to being important for healthy breast development, these hormones also perform a function in inconsistent cell changes and define the most cancer growth. It is generally believed that estrogen mainly plays an important role in pathophysiology for the most cancer. By attaching estrogen receptors to the surfaces of the chest cells, the hormone triggers signaling pathways that cause cellular division and spread. It has brought a significant portion of the breast tumor classified as estrogen receptor Fantastic (Al-Shami, et al., 2023).

However, hormones play a complicated function in pathophysiology for breast maximum cancers. Although the frame's hormonal environment plays a feature in the development of most cancers, the tumor itself can show a dynamic interplay with those hormones. For instance, the tumor has the functionality to expand a hormone -unbiased passage over the years that would result in resistance to remedy and illness. It is the cause of a serious problem for most of the breast cancer that causes hormonal suppliers that block the effect of estrogen, as well as fragrant inhibitors and selective estrogen receptor modulator (SERM) may lose performance under tumor adjustments (Satpathi, et al., 2023).

The interaction between estrogen and separate signal molecules makes the hormonal mobility of breast cancer more complex. For example, progesterone collaborates, another hormone required for improvement of breast tissue, often with estrogen to control mobile behavior. Progesterone receptor (PR) expression proves important to understand the aggression and duty of specific breast tumors, especially for hormone therapy (Manavathi, et al., 2013).

Recent development in molecular biology and genetics has improved our information of the cellular device that the hormone signaling routes motive breast most cancers. This progress has identified capacity dreams for scientific intervention alongside the identification of recent biomarkers to hit upon and are expecting breast cancer. In addition, non-hormonal variables that engage with hormonal squares to affect tumors and metastasis now are hormonal dynamics due to an understanding of the enlargement of the immune machine's work inside the biology of breast cancer and the tumor microphy. Understanding the dynamics of breast cancer hormones is essential for growing both treatment plans and expertise of biology inside the situation. Hormonal cures together with tamoxifen and aromatase inhibitors have converted the management of estrogen receptor-wonderful breast cancer, enhancing each affected person survival rates and great of lifestyles. However, resistance to those remedies is still a primary problem, which emphasizes the want to research more in molecular procedures in the back of hormonal signaling and treatment resistance (Passaro et al., 2024).

This review study focuses on the mechanistic effects of estrogen, progesterone, and HER2 on breast cancer development and progression. In addition, evaluation attempts to offer a complete remark by looking on the effect of hormone therapy with estrogen, progesterone and different hormones to play hormones and pass on inside the area of breast cancer research and treatment.

2. Breast Cancer

It is a complicated sickness with many underlying reasons, and it's far known that hormones are an essential contributor to its pathophysiology. One of the maximums

not unusual forces that affect girls globally is breast most cancers. This contamination is elaborate, involving a couple of risk factors and underlying approaches that have an impact on its onset and development. For these purposes, the breasts have been strongly inspired by hormonal imbalances of most cancer. The mile is required to understand our knowledge of this difficulty and understand the complex courtyard between hormonal imbalance and the most cancer development of the breast, to beautify our knowledge and increase preventive and treatment strategies (Satpathi, et al., 2023).

Figure 1. The Symptom of Breast Cancer

An unbalanced evaporation of cells in the breast tissue acts as a specific function of most cancer. This is the second most common goal for cancer being international, and cancer women are recognized maximum regularly. The incidence of breast cancer varies among the population, some dangerous factors such as age, relative journal circles and a potential member of the disease with genetic deviations. In addition to affecting physical shape, breast cancer affects the existence and psychologist properly (Alkabban & Ferguson, 2023).



Figure 2. Partition Of Breast Cancer (Aly et al., 2024).

The importance of regulating hormones in breast tissue and cancer improvement has been postponed through several studies done over time. Hormone estrogen, progesterone and androgen are important for everyday breast cellular boom and functions. Estrogen, a hormone predominantly produced inside the ovaries, plays a critical role in the growth and development of breast tissue. Similarly, the menstrual cycle and breast improvement are regulated by way of progesterone, another hormone that is in most cases produced in the ovaries (Brisken & O'Malley, 2010).

3. Hormonal Imbalance and Breast Cancer

Numerous studies have connected the development and progression of breast cancer to hormonal imbalances, particularly with respect to estrogen and progesterone levels. The hormone estrogen, which is primarily produced by the ovaries, plays a crucial role in the growth and development of breast tissue. It promotes cellular replication and regulates gene expression throughout the progression of the cell cycle and during apoptosis. Progesterone, an essential hormone primarily produced in the ovaries, is crucial for regulating the menstrual cycle and breast development in individuals. It should also be stressed that although breast cancer is less common in males, it can still affect men. Working together with estrogen, it prepares breast tissue for a possible pregnancy

and supports the growth and maturation of mammary gland cells (Smith-Bindman, 2012; Cable & Grider,2020).

3.1 Mechanism of Hormonal Imbalance and Its Impact on Breast Tissue

A hormonal imbalance is characterized by a deviation or disruption of the body's optimal hormone levels or ratios. Nonetheless, it is important to remember that because of personal variances and the complex relationships between hormones, identifying a specific numerical ratio or hormone level as "balanced" or "normal" can be challenging (Cable & Grider,2020). Breast cancer can be influenced by hormonal imbalance through the activation of estrogen receptors (ERs) and progesterone receptors (PRs) in breast cells. The binding of estrogen to ER or progesterone to PR triggers a complex series of intracellular signaling events that can aid in regulating cell proliferation and preventing cell death (Cheng et al., 2022). These pathways can become dysregulated when there is an excess of estrogen or when progesterone signaling is compromised, resulting in uncontrolled cell proliferation and tumor formation. Hormonal imbalances can also influence the microlensing of breast tissue. As an example, estrogen enhances the production of growth factors and promotes blood vessel development, both in angiogenesis and tumor dissemination. This tumor can also alter immune surveillance and promote immune system theft by impacting the immune response in the chest area (Satpathi, et al., 2023).

4. Physiological Roles of Key Hormones in Breast Tissue Development

However, changes in receptor signaling and hormonal balance can begin and encourage the growth of breast tissue of cancer. The physical function of these hormones, their impact on carcinogenesis, and the consequences of hormonal imbalance in various types of breast cancer. It also examines how advances in our understanding of hormonal signaling have facilitated the development of analog treatments like aromatase inhibitors and selective estrogen receptor modulators (SERMs) (Agnoletto & Brisken, 2025).

4.1 Estrogen and Nipple Growth

Estrogen is one of the hormones most studied in relation to breast cancer due to its crucial role in promoting the growth and development of breast tissue. It is synthesized in the ovaries, adrenal glands and other tissues. Estrogen improves the effects of committing estrogen receptors (ER), which are transcription factors that regulate gene expression. This receptor binding is crucial for maintaining normal breast tissue architecture and function, particularly during puberty, menstruation, and pregnancy (Al-Shami, et al., 2023).

Estrogen affects the multiplication of breast epithelial cells, the development of ducts, and the maturation of glandular tissue. In the normal breast, estrogen supports the regulation of processes such as cell cycle progression, apoptosis (programmed cell death), and tissue repair. However, for breast cancer, estrogen can function as a powerful mitogen, propelling the abnormal growth of cells. Breast cancers that express estrogen receptors (ER-positive) are known to respond to estrogen-driven signals, which can contribute to tumor growth and metastasis. This relationship is a key factor in the pathogenesis of many breast cancers (Wang, & Di, 2014).

4.2 Progesterone's Role in Breast Tissue and Cancer

Progesterone is another essential hormone for normal breast tissue development. In conjunction with estrogen, progesterone is involved in regulating the development and maturation of breast tissue, especially during the luteal phase of the menstrual cycle and throughout pregnancy. Progesterone receptors (PR) in breast tissue respond to this hormone by activating signaling pathways that regulate cell differentiation and function (Li, et al., 2022).

With regard to breast cancer, progesterone functions as a proliferative agent. Its effects, however, are often seen as more modulatory compared to estrogen, working in conjunction with estrogen to regulate the growth and differentiation of breast tissue. Research indicates that breast cancer patients with progesterone receptors have a better prognosis, as PR-positive tumors are typically less aggressive than their PR-negative counterparts. However, hormonal fluctuations in progesterone levels can contribute to the progression of hormone receptor-positive breast cancers by promoting cell

cycle progression and inhibiting apoptosis (Trabert et al., 2020).

4.3 Androgens and Their Impact on Breast Cancer

Androgens, primarily testosterone and its more potent metabolite dihydrotestosterone, are typically associated with male physiology. However, androgens are also present in women and have been found to play a role in breast tissue development and cancer. In premenopausal women, androgens are produced in the ovaries and adrenal glands, and in postmenopausal women, androgens are converted into estrogen in peripheral tissues like adipose tissue (hrane et al., 2014).

Androgens have both direct and indirect effects on breast cancer. Some studies suggest that androgens may act as growth inhibitors in some types of breast cancer. Nonetheless, the role they play is intricate; androgens can have pro-carcinogenic effects by stimulating the growth of breast cancer cells that are positive for androgen receptors (AR). In addition, the balance between estrogen and androgen signaling is crucial in determining the aggressiveness and hormone responsiveness of breast cancer. Androgen signaling can also interact with estrogen and progesterone signaling pathways, contributing to tumor progression (Takagi et al., 2022).

5. Mechanism Through Which Hormonal Imbalance Contribute to Carcinogenesis

5.1 Abnormal Cell Proliferation

One of the fundamental mechanisms through which hormones contribute to carcinogenesis is the dysregulation of cell proliferation. Under normal conditions, hormonal signals control the timing and rate of cell division, ensuring that tissue growth occurs in a controlled manner. However, in breast cancer, the presence of excess estrogen or progesterone can promote uncontrolled cell proliferation. In particular, estrogen can attach to the estrogen receptor (ER), thereby activating transcription factors that enhance the expression of genes related to cell cycle progression and survival (Zhang, et al., 2024).

In ER-positive breast cancer, the continuous stimulation by estrogen can lead to sustained proliferation, contributing to tumor growth. Moreover, mutations or overexpression of estrogen and progesterone receptors can enhance the proliferative effects of these hormones. The imbalanced expression of hormone receptors, such as overexpression of ER or PR, leads to the activation of cell cycle regulators and prevents normal apoptosis, further exacerbating tumor development (Miziak et al., 2023).

5.2 Resistance to Apoptosis

Apoptosis (or programmed cell death) serves as a natural defense mechanism to prevent the proliferation of damaged or abnormal cells. The breast can prevent hormonal imbalance apoptosis in maximum cancer, allowing malignant cells to live and move uncontrollably. Estrogen and progesterone were validated to increase anti-apoptotic results by promoting the expression of surviving proteins such as BCL-2 and interfering with pro-apoptic factors such as P53. This intervention with simple apoptotic routes provides further evidence of breast cancer cells against chemotherapy and radiation, which contributes to the failure and propulsion of tumor. Furthermore, hormonal remedy, which include tamoxifen, which blocks estrogen signaling, has been proven to repair the sensitivity of breast most cancers cells to apoptosis. However, over time, some tumors amplify resistance to hormonal treatment plans, main to greater competitive cancer behavior and metastasis (He et al., 2024).

5.3 Genomic Instability

The Hormonal imbalances can also contribute to genomic instability, a hallmark of most cancers. Estrogen has been validated to result in DNA harm thru the technology of reactive oxygen species (ROS), that may cause mutations in key genes that alter cell growth, differentiation, and apoptosis. Over time, the accumulation of genetic mutations can motive the malignant transformation of regular breast cells (Di Sante et al, 2017).

In addition, hormonal signaling can modify chromosome and gene expression profiles in breast tissue, increasing the risk of

cancer growth. In the repair, processes for mutation -DNA in tumor limitation genes such as TP53, BRCA1 and BRCA2 key actors -can increase the sensitivity of breast cancer, especially about hormonal signaling (Carbone et al.,2025).

6. Hormonal Dysregulation and Breast Cancer Subtypes

Some breast most cancers subtypes are closely associated with hormonal imbalance. Variations in their responsiveness to treatment, as well as unique molecular and histological characteristics (Orrantia-Borunda et al., 2022) characterize these subtypes.

6.1 Luminal A and Luminal B Subtypes

Although both Luminal A and Luminal B breast cancers are ER+ subtypes, they vary in how quickly they proliferate and react to treatment. Luminal A malignancies typically have a better prognosis, a lower grade, and a slower growth rate. Usually, these cancers respond well to hormonal treatments that inhibit the action of estrogen, like aromatase inhibitors or selective estrogen receptor modulators (SERMs) (Orrantia-Borunda et al., 2022).

However, luminal B tumors have a more aggressive clinical history, higher histologic grade, and higher rates of proliferation. Over time, luminal B cancers may become resistant to hormonal therapy even though they are still estrogen receptor-positive. Changes in hormone receptor expression, mutations in important signaling pathways, or the emergence of alternative growth pathways that circumvent hormonal regulation are thought to be the main causes of this resistance (Orrantia-Borunda et al., 2022).

6.2 The HER2-Positive and Triple-Negative Breast Cancer Subtypes

The HER2-positive and triple-negative breast cancer subtypes are noteworthy because they have different molecular profiles and hormonal interactions, even though they are not directly caused by hormone signaling. HER2-positive breast cancers overexpress the human epidermal growth factor receptor 2 (HER2), leading to increased cell proliferation. These cancers often co-exist with hormonal receptor positivity, and targeted therapies like trastuzumab (Herceptin) are used to block HER2 signaling. However, hormone therapy may be less effective in HER2-positive cases that also lack estrogen and progesterone receptors (triple-negative) (Alanko et al., 2021).

7. Targeted Hormonal Therapies

Advances of hormonal dynamics have informed the development of targeted treatments for breast cancer. The primary categories of therapies comprise selective estrogen receptor modulators (SERMs) and aromatase inhibitors (Iacopetta, et al., 2023).

7.1 Selective Estrogen Receptor Modulators (SERMs)

SERMs such as tamoxifen function by attaching to the estrogen receptor, thereby preventing estrogen's effects in breast cancer cells. It has been demonstrated that amoxifen decreases the recurrence rate and enhances survival rates in cases of ER-positive breast cancer. However, if cancers develop resistance mechanisms, its effectiveness may diminish over time (Howell et al.,2004).

7.2 Aromatase Inhibitors

Letrozole and anastrozole are examples of aromatase inhibitors, which prevent the enzyme aromatase from converting androgens into estrogen. These medications are frequently used to lower estrogen levels and stop the growth of ER-positive tumors in postmenopausal women. For the best therapeutic results, aromatase inhibitors are frequently used in conjunction with other therapies (Chumsri et al., 2011).

A type of hormones and signaling pathways are involved within the complicated hormonal dynamics of breast cancer, which have an effect on the onset, path, and reaction to treatment. Effective hormone remedies were developed because of a higher expertise of those hormonal interactions, which have additionally yielded critical insights into the pathophysiology of breast cancer. In order to create extra individualized and centered remedies for patients with breast most cancers, additional take a look at into the molecular

pathways at the back of hormone dysregulation is crucial (Satpathi et al., 2023).

8. Mechanism Pathways of Estrogen, Progesterone and HER2.

The hormonal regulation of breast cancer involves complex interactions among estrogen (ER), progesterone (PR), and HER2 signaling pathways. These molecules collectively influence cell proliferation, differentiation, survival, and resistance to therapy. Understanding how they interacted provides crucial insight into breast cancer progression and the rationale for targeted endocrine and molecule therapies (Miziak, et al., 2023).

8.1 Estrogen Mechanism

Estrogen acts primarily through estrogen receptors (ERα and ERβ) which are unclear receptor transcription factors. Upon hormone binding ERα translocated to the nucleus and binds to estrogen response elements (EREs) in DNA, promoting transcription of genes involved in cell cycle control (cyclin D1, C-Myc), inhibition of apoptosis, angiogenesis (VEGF), and proliferation of epithelial cells. Estrogen also activates non-genomic signaling through membrane-associated ERs, stimulating MAPK and P13K/AKT pathways, which enhance cell growth and survival. Chronic estrogen stimulation leads to DNA damage and oxidative stress, increasing mutation rates and tumorigenic potential (Fuentes & Silveyra, 2019).

8.2 Progesterone Mechanism

Progesterone functions via progesterone receptor isoforms (PR-A and PR-B), which can modulate both estrogen and growth factor signaling. Under normal physiological conditions, progesterone induces cell differentiation and limits excessive proliferation. In cancerous tissue, especially in ER+/PR+ tumors, progesterone can enhance estrogen-driven proliferation through PR-ER cross talk.

Mechanistically, progesterone signaling activates PANKL/NF-ΚB, STAT3, and MAPK pathways, which contribute to expansion of mammary stem cell, enhanced cell division, and increased metastatic potential. The RANKL axis plats a particularly significant role in linking progesterone signaling to inflammation and tumor initiation (Brisken & Scabia 2020).

8.3 HER2 Mechanism and Its Crosstalk with Er/Pr

HER2 (Human Epidermal Growth Factor Receptor 2) is a tyrosine kinase receptor that belongs to the EGFR (ErbB) family. HER2 activation triggers strong proliferation and survival signals through MAPK/ERK, PI3K/AKT/ Motor, and JAK/STAT pathways.

Overexpression or amplification of HER2 is observed in about 15-10% of breast cancers and is associated with aggressive tumor behavior, rapid growth, and poor prognosis. Importantly, HER2 signaling can interact with estrogen and progesterone receptors: Estrogen receptor activation may upregulate HER2 expression, creating a feedback loop that strengthens tumor growth. Conversely, HER2 activation can phosphorylate ER, leading to ligand- independent activation, meaning the cancer can grow even in the absence of estrogen. This cross activation contributes to endocrine resistance, explaining why some ER+ tumors become unresponsive therapy (Rubin et al., 2024).

9. The Expression of ER, PR And Her2 and Their Impact on Treatment Decisions and Patient Outcomes

In order to categories breast most cancers subtypes and pick the excellent treatment approaches, the expression of HER2 and hormone receptors (ER and PR) is vital. The biology of the tumor and its ability response to exclusive remedy pills are crucially revealed by way of these signs (Liu et al., 2025).

9.1 Expression of the Estrogen Receptor (ER)

One of the maximum full-size indicators of breast cancer is the expression of the estrogen receptor (ER), which helps to recognize tumors that may respond to endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators (SERMs). Compared to ER-bad breast cancers, ER-fantastic breast cancers generally grow greater slowly and have a higher prognosis.

Hormone treatments that decrease estrogen synthesis or prevent estrogen from attaching to its receptor can greatly decrease the risk of recurrence and boom survival costs. ER reputation is intently related to the effectiveness of medicines including aromatase inhibitors, which suppress estrogen levels in postmenopausal women, and tamoxifen, a SERM. These remedies, which are important for treating each early-degree and metastatic breast cancer, usually work higher for sufferers with ER-high quality tumors (Miziak et al., 2023).

9.2 Progesterone Receptor (PR) Expression

Since cancers that test fantastic for both receptors generally have a better prognosis and are more likely to react to hormone remedy, progesterone receptor (PR) expression is regularly taken under consideration together with ER fame. While PR-terrible cancers might be more proof against hormonal remedies, PR-wonderful tumors are related to a decrease grade and much less aggressive conduct.

PR fame is important for figuring out the satisfactory direction of treatment as well as for prognostic considerations. While the significance of PR expression is often secondary to ER reputation, its presence can useful resource further stratify breast most cancers patients and guide therapy selection (Hefti et al., 2013).

9.3 Overexpression of HER2

About 15–25% of breast tumors show case overexpression of the receptor tyrosine kinase HER2. When it comes to boom and recurrence, HER2-tremendous breast cancers are usually more aggressive than HER2-negative ones. The prognosis for patients with HER2-fantastic breast most cancers has improved dramatically, even though, because the development of centered treatments like trastuzumab (Herceptin).

Trastuzumab blocks the signaling pathways that encourage the increase of cancer cells by using selectively concentrated on and inhibiting the HER2 receptor. In addition, new HER2-focused treatment processes, combined with Peruzumab and T-DM1, have survival costs for HER2-Nice victims, especially people with metastatic diseases (Iqbal & Iqbal, 2014).

10. The Intersection of Clinicopathological Features and Hormonal Dynamics in Women Breast Cancer

One of the most unusual cancers in Girls International is the most cancer. Hormonal dynamics play an important component in its complex etiology, including both hereditary and environmental variables. Improvement of breast cancer, orbit and results are associated with hormones such as estrogen, progesterone and androgens. For individual treatment plans and better patient effects, it is necessary to identify how hormonal dynamics are attached to the clinic pathological properties of breast cancer, include tumor forms, characters, levels and receptors. With an emphasis on their roles in tumor biology, analysis, and remedy choices, this chapter tries to research how hormone variables have an effect on the clinicopathological functions of breast cancer in women (Satpathi et al., 2023).

11. Hormonal Dynamics in Breast Cancer Pathogenesis

The proper growth and operation of breast tissue rely heavily on hormones. In the breast, estrogen and progesterone specially control critical functions like cellular division, proliferation, and apoptosis. However, whilst those hormonal pathways are dysregulated, they are able to contribute to the improvement of breast cancer. Hormonal exposure is a known risk factor, with estrogen acting as a potent mitogen that can promote the growth of hormone receptor-positive (HR-positive) breast cancers (Clusan et al., 2023).

11.1 The Mechanisms by Which Hormonal Dysregulation Promotes Breast Cancer Include:

- Abnormal cell proliferation: Estrogen and progesterone stimulate cell division and growth in breast tissue. When these hormones are unregulated, it can result in uncontrolled cell proliferation, a hallmark of cancer development.
- Resistance to apoptosis: Hormones can also inhibit cell death (apoptosis) by activating survival, pathways, allowing abnormal cells to survive and accumulate

mutations, further enhancing tumorigenesis.

- Genomic instability: Estrogen-induced DNA damage and mutations can lead to genomic instability, which is often observed in hormone-dependent cancers and can drive tumor progression (Sciences et al., 2016).

12. The Role of Hormonal Receptors in Clinicopathological Feature

One of the most important clinicopathological features in breast cancer is the expression of hormone receptors—specifically, estrogen receptors (ER), progesterone receptors (PR), and HER2 (human epidermal growth factor receptor. These receptors are crucial in determining both prognosis and treatment strategies (Rodrigues et al., 2024).

12.1 Estrogen and Progesterone Receptors (ER and PR)

- **ER-positive tumors:** Tumors that express estrogen receptors (ER-positive) are more likely to be hormone-dependent, meaning their growth is influenced by estrogen. These tumors tend to grow more slowly and are often less aggressive compared to ER-negative tumors. ER-positive breast cancers respond well to hormone therapies, such as selective estrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors, which block the action of estrogen or reduce its production (Rodrigues et al., 2024).
- **PR-positive tumors:** Progesterone receptor (PR) status is often considered alongside estrogen receptor status. Tumors that express both ER and PR are generally associated with better prognoses. PR-positive breast cancers are also more likely to respond to hormone therapy, as they indicate a hormone-responsive phenotype (Li et al.,2022).



Figure 3. Hormonal Dynamic in Breast Cancer.

12.2 HER2 Expression

- HER2-positive tumors: HER2 is a receptor that is overexpressed in approximately 15-20% of breast cancer cases. It is associated with more aggressive tumor behavior, higher rates of recurrence, and poor prognosis. However, targeted therapies, such as trastuzumab (Herceptin), have significantly improved outcomes for HER2-positive patients, even in advanced stages. The interplay among hormonal dysregulation and HER2 overexpression also can have an impact on tumor growth and the response to therapy (Gajria & Chandarlapaty, 2011).

13. The Role of Tumer Size, Grade, And Stage in Hormonal Dynamics

The size, grade, and stage of a breast tumor are crucial factors in assessing the prognosis and determining treatment techniques. These characteristics have an impact on the condition of hormone receptors, the possibility of reacting to hormonal treatments, and are intricately linked to hormonal dynamics (Nolan et al., 2023).

13.1 Tumor Size

Estrogen receptor expression is regularly higher in large tumors, mainly in hormone-established malignancies. By attaching to estrogen receptors and selling mobile proliferation, estrogen might also sell the formation of tumors. Furthermore, large tumors are much more likely to contain lymph nodes and unfold metastatically, which could make remedy and analysis extra tough (Chimento et al., 2022).

13.2 Tumor Grade

Hormonal receptor dysregulation may be found in higher-grade tumors, which might be tons much less differentiated and have a propensity to increase more aggressively. On the other hand, low-grade tumors are much more likely to respond to endocrine remedies considering they resemble regular tissue more and frequently specific hormone receptors (Feng et al., 2018).

13.3 Tumor Stage

Because early-level tumors (Stage I and II) are circumscribed and may reply better to hormonal therapy, they are more likely to be hormone receptor-effective and have a better prognosis. However, advanced degree cancers (Stage III and IV) are much less possibly to react to hormone-based totally remedies and can showcase more competitive behavior, along with the lack of hormone receptor expression (Walsh et al., 2020).

14. Molecular Profiling and Its Impact on Hormonal Dynamics

The genetic and molecular foundations of breast most cancers may be higher understood way to molecular profiling techniques like DNA sequencing, gene expression profiling, and immunohistochemistry (IHC). These methods useful resource in figuring out a tumor's hormonal kingdom, classifying it into subtypes, and forecasting how it will react to remedy (Kittaneh et al.,2013).

14.1 Immunohistochemistry (IHC)

The expression of ER, PR, and HER2 receptors in breast maximum cancers tissue is frequently evaluated the usage of this method. IHC enables to classify breast tumors into hormone receptor-high satisfactory or awful and HER2-advantageous or awful, that is essential for selecting powerful treatments.

14.2 Gene Expression Profiling

The use of equipment just like the Oncotype DX and Mamma Print checks lets in clinicians to evaluate the gene expression styles of breast cancer tumors, predicting the danger of recurrence and the probability of profiting from chemotherapy or hormone remedy. This affords a more customized approach to treatment, tailoring alternatives based totally at the tumor's molecular profile (Takagi et al., 2022).

14.3 Next-generation sequencing (NGS)

NGS makes it viable to find out adjustments and mutations in crucial genes like TP53, PIK3CA, BRCA1, and BRCA2, which is probably concerned in hormone signaling and the improvement of maximum cancers. These mutations could have an effect on how well a affected man or woman responds to remedy and shed mild at the tactics at the back of hormonal imbalance in breast cancer (Zaha, 2014).

15. Targeted Hormonal Therapies in Breast Cancer Treatment

Targeted remedies that adjust the hormonal milieu to prevent the growth of most cancers have been developed due to a better knowledge of hormonal dynamics. Hormone receptor-advantageous cancers respond properly to those treatments (El Sayed et al.,2019).

15.1 Selective Estrogen Receptor Modulators (SERMs)

One of the most famous SERMs, tamoxifen, limits the proliferative movement of estrogen on tumor cells via preventing it from attaching to its receptor. SERMs can dramatically lower the hazard of recurrence and are commonly applied in ER-advantageous breast tumors (Criscitiello et al., 2010).

15.2 Aromatase Inhibitors

Used to treat ER-superb breast tumors, aromatase inhibitors, such letrozole and anastrozole, lower estrogen degrees inside the body, particularly in postmenopausal ladies. It has been validated that those medicines work nicely to forestall cancer from returning (Criscitiello et al., 2010).

15.3 Targeted Treatments for Tumors That Are HER2-Positive

Blocking the HER2 receptor and slowing tumor boom are the goals of trastuzumab (Herceptin) and different HER2-targeted treatments like pertuzumab. These treatments work specifically well for HER2-high-quality breast cancer, which regularly rejects traditional hormonal treatments (Criscitiello et al., 2010).

16. Conclusion

In conclusion, breast most cancers keeps to rank many of the maximum hard and complicated ailments affecting girls global. Estrogen and progesterone regulate gene transcription and cellular proliferation, while HER2 activates potent growth factor signaling cascades. Clinic pathological traits such tumor duration, grade, stage, and receptor recognition offer vital facts about how aggressive the contamination is, further to treatment options and individualized care plans. Analysis of breast cancer, diagnosis and treatment of treatment requires the expertise of related hormonal dynamics in its clinicopathological instinct along with the pathogenesis of the disease. A roadmap for individual measurement plans is delivered using trends in centered treatment and molecular diagnosis, which means that girls want better effects everywhere. Clinical testing and cooperative research can be important for fate to increase these strategies and breast's most cancer field.

References

Al-Shami, K., Awadi, S., Khamees, A., Alsheikh, A. M., Al-Sharif, S., Bereshy, R. A., et al. (2023). Estrogens and the risk of breast cancer: A narrative review of literature. Heliyon, 9(9), e20224. https://doi.org/10.1016/j.heliyon.2023.e20224

Alkabban, F. M., & Ferguson, T. (2022). Breast Cancer StatPearls. Treasure Island (FL): StatPearls Publishing.

Aly, S. H., Elbadry, A. M., Doghish, A. S., & El-Nashar, H. A. (2024). Unveiling the pharmacological potential of plant triterpenoids in breast cancer management: an updated review. Naunyn-schmiedeberg's Archives of Pharmacology, 397(8), 5571-5596. https://doi.org/10.1007/s00210-024-03054-2

Agnoletto, A., & Brisken, C. (2025). Hormone signaling in breast development and cancer. A Guide to Breast Cancer Research: From Cellular Heterogeneity and Molecular Mechanisms to Therapy, 279-307. https://doi.org/10.1007/978-3-031-70875-6_15

Alanko, J., Tanner, M., Vanninen, R., Auvinen, A., & Isola, J. (2021). Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast cancer research and treatment, 187(1), 267-274. https://doi.org/10.1007/s10549-020-06060-z

Brisken, C., & O'Malley, B. (2010). Hormone action in the mammary gland. Cold Spring Harbor perspectives in biology, 2(12), a003178. https://doi.org/10.1101/cshperspect.a003178

Brisken, C., & Scabia, V. (2020). 90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer. Journal of molecular endocrinology, 65(1), T81-T94. https://doi.org/10.1530/JME-20-0091

Cable, J. K., & Grider, M. H. (2020). Physiology, progesterone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558960/

Criscitiello, C., Fumagalli, D., Saini, K. S., & Loi, S. (2010). Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. OncoTargets and therapy, 1-11. https://doi.org/10.2147/OTT.S10155

Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023). A basic review on estrogen receptor signaling pathways in breast cancer. International journal of molecular sciences, 24(7), 6834. https://doi.org/10.3390/ijms24076834

Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D'Amato, N. C., ... & Richer, J. K. (2014). Role of the androgen

receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research, 16(1), R7. https://doi.org/10.1186/bcr3599

Cheng, C. H., Chen, L. R., & Chen, K. H. (2022). Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. International journal of molecular sciences, 23(3), 1376. https://doi.org/10.3390/ijms23031376

Carbone, F. P., Ancona, P., Volinia, S., Terrazzan, A., & Bianchi, N. (2025). Druggable molecular networks in BRCA1/BRCA2-Mutated breast cancer. Biology, 14(3), 253. https://doi.org/10.3390/biology14030253

Chimento, A., De Luca, A., Avena, P., De Amicis, F., Casaburi, I., Sirianni, R., & Pezzi, V. (2022). Estrogen receptors-mediated apoptosis in hormone-dependent cancers. International journal of molecular sciences, 23(3), 1242. https://doi.org/10.3390/ijms23031242

Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011). Aromatase, aromatase inhibitors, and breast cancer. The Journal of steroid biochemistry and molecular biology, 125(1-2), 13-22. https://doi.org/10.1016/j.jsbmb.2011.02.001

Di Sante, G., Di Rocco, A., Pupo, C., Casimiro, M. C., & Pestell, R. G. (2017). Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer. Oncotarget, 8(47), 81803. https://doi.org/10.18632/oncotarget.19413

El Sayed, R., El Jamal, L., El Iskandarani, S., Kort, J., Abdel Salam, M., & Assi, H. (2019). Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Frontiers in oncology, 9, 510. https://doi.org/10.3389/fonc.2019.00510

Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., ... & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & diseases, 5(2), 77-106. https://doi.org/10.1016/j.gendis.2018.05.001

Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in protein chemistry and structural biology, 116, 135-170. https://doi.org/10.1016/bs.apcsb.2019.01.001

Gajria, D., & Chandarlapaty, S. (2011). HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy, 11(2), 263-275. https://doi.org/10.1586/era.10.226

He, R., Liu, Y., Fu, W., He, X., Liu, S., Xiao, D., & Tao, Y. (2024). Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression. Molecular cancer, 23(1), 267. https://doi.org/10.1186/s12943-024-02172-y

Howell, S. J., Johnston, S. R., & Howell, A. (2004). The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best practice & research Clinical endocrinology & metabolism, 18(1), 47-66. https://doi.org/10.1016/j.beem.2003.08.002

Hefti, M. M., Hu, R., Knoblauch, N. W., Collins, L. C., Haibe-Kains, B., Tamimi, R. M., & Beck, A. H. (2013). Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Research, 15(4), R68. https://doi.org/10.1186/bcr3462

Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M. S., & Catalano, A. (2023). Targeting breast cancer: An overlook on current strategies. International journal of molecular sciences, 24(4), 3643. https://doi.org/10.3390/ijms24043643

Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Molecular biology international, 2014(1), 852748. https://doi.org/10.1155/2014/852748

Kittaneh, M., Montero, A. J., & Glück, S. (2013). Molecular profiling for breast cancer: a comprehensive review. Biomarkers in cancer, 5, BIC-S9455. https://doi.org/10.4137/BIC.S9455

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287

Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. (2022). The role of progesterone receptors in breast cancer. Drug design, development and therapy, 305-314. https://doi.org/10.2147/DDDT.S336643

Liu, C., Sun, L., Niu, N., Hou, P., Chen, G., Wang, H., ... & Liu, C. (2025). Molecular classification of hormone receptor-positive/HER2-

positive breast cancer reveals potential neoadjuvant therapeutic strategies. Signal transduction and targeted therapy, 10(1), 97. https://doi.org/10.1038/s41392-025-02181-3

Miziak, P., Baran, M., Błaszczak, E., Przybyszewska-Podstawka, A., Kałafut, J., Smok-Kalwat, J., ... & Stepulak, A. (2023). Estrogen receptor signaling in breast cancer. Cancers, 15(19), 4689. https://doi.org/10.3390/cancers15194689

Manavathi, B., Dey, O., Gajulapalli, V. N. R., Bhatia, R. S., Bugide, S., & Kumar, R. (2013). Derailed estrogen signaling and breast cancer: an authentic couple. Endocrine reviews, 34(1), 1-32. https://doi.org/10.1210/er.2011-1057

Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023). Deciphering breast cancer: from biology to the clinic. Cell, 186(8), 1708-1728. https://doi.org/10.1016/j.cell.2023.01.040

Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L. E., et al. (2022). Subtypes of breast cancer. In H. N. Mayrovitz (Ed.), Breast cancer. Exon Publications. https://doi.org/10.36255/exon-publications-breast-cancer-subtypes

Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., ... & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell, 187(7), 1617-1635. https://doi.org/10.1016/j.cell.2024.02.041

Rodrigues, I., Fernandes, R., Ferreira, A., Pereira, D., Fernandes, R., Soares, R., & Luís, C. (2025). Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status. Clinical Breast Cancer, 25(4), e331-e340. https://doi.org/10.1016/j.clbc.2024.11.018

Rubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Milillo-Naraine, A. M., Guaqueta, D., & Ergle, A. (2024). Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. International journal of molecular sciences, 25(2), 1064. https://doi.org/10.3390/ijms25021064

Satpathi, S., Gaurkar, S. S., Potdukhe, A., & Wanjari, M. B. (2023). Unveiling the role of hormonal imbalance in breast cancer development: a comprehensive review. Cureus, 15(7), e41737. https://doi.org/10.7759/cureus.41737

Smith-Bindman, R. (2012). Environmental causes of breast cancer and radiation from medical imaging: findings from the Institute of Medicine report. Archives of internal medicine, 172(13), 1023-1027.

Blackadar, C. B. (2016). Historical review of the causes of cancer. World journal of clinical oncology, 7(1), 54. https://doi.org/10.5306/wjco.v7.i1.54

Trabert, B., Bauer, D. C., Buist, D. S., Cauley, J. A., Falk, R. T., Geczik, A. M., ... & Brinton, L. A. (2020). Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA network open, 3(4), e203645.

Takagi, K., Yamaguchi, M., Miyashita, M., Sasano, H., & Suzuki, T. (2022). Diverse role of androgen action in human breast cancer. Endocrine Oncology, 2(1), R102-R111. https://doi.org/10.1530/EO-22-0048

Walsh, E. M., Smith, K. L., & Stearns, V. (2020, August). Management of hormone receptor-positive, HER2-negative early breast cancer. In Seminars in oncology (Vol. 47, No. 4, pp. 187-200). WB Saunders. https://doi.org/10.1053/j.seminoncol.2020.05.010

Wang, X., & Xue, Y. (2023). Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER (-)/PR (+). Frontiers in Endocrinology, 14, 1193592. https://doi.org/10.3389/fendo.2023.1193592

Wang, L., & Di, L. J. (2014). BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?. International journal of biological sciences, 10(5), 566. https://doi.org/10.7150/ijbs.8579

Wu, Z., Xia, F., & Lin, R. (2024). Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021. Journal of hematology & oncology, 17(1), 119. https://doi.org/10.1186/s13045-024-01640-8

Zaha, D. C. (2014). Significance of immunohistochemistry in breast cancer. World journal of clinical oncology, 5(3), 382. https://doi.org/10.5306/wjco.v5.i3.382

Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., ... & Wu, C. (2024). Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal transduction and targeted therapy, 9(1), 149. https://doi.org/10.1038/s41392-024-01848-7